Announcement- PLX3397 Will Have A Substantial Role In Almost Any Management

The present study shows that older as compared with younger men with Gleason score 6 and 7 prostate cancer have an increased risk of prostate cancer-specific mortality. This may be due to the presence of occult high-grade disease and suggests further diagnostic studies, e.g. multiparametric MRI, may be indicated in these men to reduce biopsy sampling error. To determine if advancing age is a risk factor for high-grade prostate cancer due to occult high-grade disease in elderly http://www.selleck.cn/products/nlg919.html men with Gleason score 6 or 7 prostate cancer. We investigated whether advancing age is associated with the risk of prostate cancer-specific mortality (PCSM) within established Gleason score categories adjusting for known predictors of PCSM. Using data from the Surveillance, Epidemiology and End Results database between 1 January 2004 to 31 December 2007, 166?104 men with non-metastatic prostate cancer were identified and formed the study cohort. After adjusting for treatment and prognostic factors, Gleason score 8�C10 and 7 as compared with ��6 was associated with an increased risk of PCSM (P http://www.selleckchem.com/products/pexidartinib-plx3397.html of Evidence?2b What��s known on the subject? and What does the study add? The Epstein criteria, which utilize prostate specific antigen density (PSAD) benchmarks, are recognized to be a reasonable method of selecting men for active surveillance of prostate cancer. Transrectal ultrasonography, however, may not be a sufficiently precise method of measuring prostate volume for the determination of PSAD. This study shows that despite impressive intra-observer variability in transrectal ultrasonography guided prostate volume measurements, this variability typically does not affect the PSAD to an extent by which qualification for active http://www.selleckchem.com/products/bmn-673.html surveillance would be altered. To determine intra-observer variability in transrectal ultrasonography (TRUS) guided prostate volume measurements in the Johns Hopkins active surveillance group and to establish whether or not this variability could affect prostate-specific antigen density (PSAD) estimates in this cohort. In all, 253 patients with a combined total of 1111 prostate biopsies underwent TRUS-guided prostate volume measurements performed by the same physician at least three times over the course of their care. Coefficients of variation (CV) were calculated for each set of measurements performed on each patient by the same physician, and average CVs were determined for each physician and for physicians overall. The CVs were correlated with the average of each patient��s measured prostate volumes to look for any trend.